Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX sequential S-1 in advanced biliary and pancreatic cancer
NCT01811277Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jul 2010
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in biliary tract cancer (BTC), periampullary cancer and pancreatic cancer (PC), sponsored by Peking University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
tegafur
03
Conditions
biliary tract cancer (BTC)periampullary cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01811277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811277.